GLOW COMPLETES SUCCESSFUL PILOT PRODUCTION OF MYCELL™ LIQUID IN CANADA
Swiss PharmaCan AG is pleased to announce that Glow LifeTech Corp. has further accelerated its path to commercialization following its successful pilot-scale production and the expansion of MyCell™ cannabis ingredient portfolio with the development of liquid MyCell™ CBN and CBG to address the emerging market demand for rare cannabinoids.
Swiss PharmaCan AG
July 13, 2023
Swiss PharmaCan AG is pleased to announce that Glow LifeTech Corp. (CSE: GLOW) (OTCQB:GLWLF) (FSE: 9DO) has further accelerated its path to commercialization following its successful pilot-scale production and the expansion of MyCell™ cannabis ingredient portfolio with the development of liquid MyCell™ CBN and CBG to address the emerging market demand for rare cannabinoids.
“Today, Glow LifeTech Corp. is an indispensable link in the worldwide production of newly developed MyCell™ formulations, either nutraceuticals, cannabinoids or cosmetics in Northern America and Mexico,” said Michel Fässler, Founder and Chief Executive Officer, Swiss PharmaCan AG. “This expansion is a major breakthrough and offers incredible opportunities to the nutraceutical industry globally. Glow LifeTech committed itself to high-quality standards while delivering and developing safe and reliable products for a wide range of applications. Furthermore, these developments took place in Glow’s Canadian cannabis processing facility that is fully licensed by Health Canada, enabling legal cannabis production for Canada and beyond.”
“This important milestone marks a major inflection point for Glow and our commercial path to market in Canada,” said Rob Carducci, Chief Commercial Officer, Glow LifeTech. “With a deep portfolio of cutting-edge cannabis ingredients, now ready for commercial production, we are in a strong position to advance our launch plans into the Canadian market.”
“Our team is focused on pushing the boundaries of innovation and performance of natural health applications using of cutting-edge technologies,” said Tom Glawdel, Chief Operating Officer, Glow LifeTech. “MyCell™ CBN and CBG unlocks a step-change in performance of rare cannabinoids with faster-onset, improved bioavailability and precision dosing, with a virtually tasteless profile.”
Glow LifeTech Corp. has an exclusive license agreement with MyCell™ Technology in North America and Mexico to develop and commercialize the next generation of scientifically proven nutraceuticals.
Researcher teams at Swiss PharmaCan AG have spent the past years conducting clinical studies that have proven the improved bioavailability of MyCell™ formulations and effectiveness at supporting the function of the immune system and regeneration processes in in-vivo clinical studies. “We are committed to advancing the science of nutraceuticals, where low bioavailability represents a persistent unmet need,” said Prof. Dr. Matevž Pompe, Head of Research and Development. “A tenet to our continued innovation is a focus on accelerating the development of MyCell™ Technology, as we strive to profoundly transform the outcomes and, ultimately, progress the potential of nutraceuticals to a prevention and regeneration process.”
The Swiss scientists behind MyCell™ Technology have achieved the goal of transforming substances with low, even undetectable absorption into formulations with near-complete bioavailability. Nutraceuticals improved by ground-breaking MyCell™ Technology are aimed to stimulate natural biological functions for vitality, rejuvenation, and regeneration.